N Stefan, K Kantartzis, HU Haring - Endocrine Reviews, 2008 - Endocrine Soc Type 2 diabetes and cardiovascular disease represent a serious threat to the health of the population
worldwide. Although overall adiposity and particularly visceral adiposity are established risk
factors for these diseases, in the recent years fatty liver emerged as an additional and ... Cited by 15 - Related articles - All 4 versions
- ►endojournals.org I Dostalova, P Kavalkova, D Haluzikova, Z … - Journal of Clinical …, 2008 - Endocrine Soc Context: Fibroblast growth factor 19 (FGF19) and FGF21 are novel metabolic regulators that
improve insulin sensitivity and decrease adiposity in mice. However, little is known about the
nutritional regulation of these factors in humans. ... Objective: The objective of this study ... Cited by 11 - Related articles - All 3 versions
K Oishi, D Uchida, N Ishida - FEBS letters, 2008 - Elsevier Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor that regulates the
expression of genes associated with lipid metabolism. Recent studies have suggested that the
expression of PPARα-dependent fibroblast growth factor 21 (FGF21) plays important ... Cited by 7 - Related articles - All 5 versions
R Micanovic, DW Raches, JD Dunbar, DA Driver, … - J Cell …, 2009 - interscience.wiley.com Fibroblast growth factor 21 is a member of endocrine FGFs subfamily, along with FGF19 and
FGF23. It is emerging as a novel regulator with beneficial effects on a variety of metabolic
parameters, including glucose and lipid control. FGF21 activity depends on membrane ... Cited by 5 - Related articles - All 2 versions
H Li, Y Bao, A Xu, X Pan, J Lu, H Wu, H Lu, K … - Journal of Clinical …, 2009 - Endocrine Soc Design: Serum FGF21 levels were determined by ELISA in 134 normal glucose tolerance
(NGT), 101 isolated-impaired fasting glucose, and 118 isolated-impaired glucose tolerance
(I-IGT) Chinese subjects, and their association with parameters of adiposity, glucose, and ... Cited by 5 - Related articles - All 3 versions
ED Berglund, CY Li, HA Bina, SE Lynes, MD Michael, … - Endocrinology, 2009 - Endocrine Soc Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator shown to improve glycemic
control. However, the molecular and functional mechanisms underlying FGF21-mediated improvements
in glycemic control are not completely understood. We examined FGF21 effects on insulin ... Cited by 3 - Related articles - All 3 versions
M León-Latre, P Mazón-Ramos, E Marcos, E García- … - Rev Esp Cardiol, 2009 - revespcardiol.org En este artículo se revisan los principales avances publicados en la prevención de las enfermedades
cardiovasculares en el último año, así como los nuevos documentos de consenso. Como en
años precedentes, buena parte del esfuerzo investigador está relacionado con las ... Cited by 2 - Related articles - Cached - All 5 versions
C Christodoulides, P Dyson, D Sprecher, K … - Journal of Clinical …, 2009 - Endocrine Soc 1 Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford,
UK. 2 NIHR Oxford Biomedical Research Centre, ORH Trust, Churchill Hospital, Oxford, UK 3
Cardiovascular and Urogenital Centre for Excellence in Drug Discovery, ... Cited by 1 - Related articles - All 2 versions
M Rydén - Cellular and Molecular Life Sciences, 2009 - Springer Abstract Fibroblast growth factor 21 (FGF21) has been proposed as a novel putative therapeutic
agent in type 2 diabetes. A large amount of data, predominantly obtained from murine models
but also from non-human primates, suggest that FGF21 ameliorates obesity-associated ... Cited by 1 - Related articles - All 2 versions
S Stein, A Bachmann, U Lössner, J Kratzsch, M … - Diabetes Care, 2009 - Am Diabetes Assoc OBJECTIVE—To investigate renal elimination of the adipokine fibroblast growth factor 21
(FGF21) by determining circulating FGF21 levels in patients on chronic hemodialysis (CD) as
compared with control subjects with a glomerular filtration rate (GFR) >50 ml/min. Cited by 1 - Related articles - All 3 versions
